{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T01:52:52Z","timestamp":1781574772521,"version":"3.54.5"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.82302586"],"award-info":[{"award-number":["No.82302586"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Scientific Research Launch Project for new employees of the Second Xiangya Hospital of Central South University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04842-1","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:36:30Z","timestamp":1777451790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel serum metabolite classifier for identifying Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) integrating metabolomics and machine learning"],"prefix":"10.1186","volume":"26","author":[{"given":"Binghui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lini","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qichen","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"6","key":"4842_CR1","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542\u201356.","journal-title":"J Hepatol"},{"issue":"7","key":"4842_CR2","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","volume":"158","author":"TG Cotter","year":"2020","unstructured":"Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158(7):1851\u201364.","journal-title":"Gastroenterology"},{"issue":"5","key":"4842_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389\u201398.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"4842_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jama.2025.19615","volume":"335","author":"H Tilg","year":"2026","unstructured":"Tilg H, Petta S, Stefan N, Targher G. Metabolic dysfunction-associated steatotic liver disease in adults: a review. JAMA. 2026;335(2):163\u201374.","journal-title":"JAMA"},{"issue":"Suppl","key":"4842_CR5","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31(Suppl):S32\u201350.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"4842_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"4842_CR7","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908\u201322.","journal-title":"Nat Med"},{"issue":"7","key":"4842_CR8","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","volume":"70","author":"TG Simon","year":"2021","unstructured":"Simon TG, Roelstraete B, Khalili H, Hagstrom H, Ludvigsson JF. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut. 2021;70(7):1375\u201382.","journal-title":"Gut"},{"key":"4842_CR9","doi-asserted-by":"publisher","unstructured":"Guo X, Yin X, Liu Z, Wang J. Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232415489.","DOI":"10.3390\/ijms232415489"},{"issue":"1","key":"4842_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cmet.2020.11.010","volume":"33","author":"SR Sharpton","year":"2021","unstructured":"Sharpton SR, Schnabl B, Knight R, Loomba R. Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease. Cell Metab. 2021;33(1):21\u201332.","journal-title":"Cell Metab"},{"issue":"1","key":"4842_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/hep.29721","volume":"68","author":"ZM Younossi","year":"2018","unstructured":"Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018;68(1):349\u201360.","journal-title":"Hepatology"},{"issue":"7","key":"4842_CR12","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J, International Consensus P. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999\u20132014. e1991.","journal-title":"Gastroenterology"},{"issue":"3","key":"4842_CR13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2337\/dc16-1787","volume":"40","author":"F Bril","year":"2017","unstructured":"Bril F, Cusi K. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Diabetes Care. 2017;40(3):419\u201330.","journal-title":"Diabetes Care"},{"issue":"32","key":"4842_CR14","doi-asserted-by":"publisher","first-page":"7236","DOI":"10.3748\/wjg.v22.i32.7236","volume":"22","author":"I Mikolasevic","year":"2016","unstructured":"Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography (FibroScan((R))) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? World J Gastroenterol. 2016;22(32):7236\u201351.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"4842_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4292\/wjgpt.v7.i1.91","volume":"7","author":"PE Chang","year":"2016","unstructured":"Chang PE, Goh GB, Ngu JH, Tan HK, Tan CK. Clinical applications, limitations and future role of transient elastography in the management of liver disease. World J Gastrointest Pharmacol Ther. 2016;7(1):91\u2013106.","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"4842_CR16","doi-asserted-by":"publisher","first-page":"1050439","DOI":"10.3389\/frai.2022.1050439","volume":"5","author":"C Baciu","year":"2022","unstructured":"Baciu C, Xu C, Alim M, Prayitno K, Bhat M. Artificial intelligence applied to omics data in liver diseases: Enhancing clinical predictions. Front Artif Intell. 2022;5:1050439.","journal-title":"Front Artif Intell"},{"issue":"12","key":"4842_CR17","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41575-021-00502-9","volume":"18","author":"M Masoodi","year":"2021","unstructured":"Masoodi M, Gastaldelli A, Hyotylainen T, Arretxe E, Alonso C, Gaggini M, et al. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat Rev Gastroenterol Hepatol. 2021;18(12):835\u201356.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"4842_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11306-021-01810-6","volume":"17","author":"FN Mazzini","year":"2021","unstructured":"Mazzini FN, Cook F, Gounarides J, Marciano S, Haddad L, Tamaroff AJ, et al. Plasma and stool metabolomics to identify microbiota derived-biomarkers of metabolic dysfunction-associated fatty liver disease: effect of PNPLA3 genotype. Metabolomics. 2021;17(7):58.","journal-title":"Metabolomics"},{"key":"4842_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cca.2022.12.014","volume":"538","author":"L Shao","year":"2023","unstructured":"Shao L, Liu J, Song Y, Yang W, Gong L, Lyu Z, Zhu Q, Fu J, Li J, Shi J. Serum metabolomics-based heterogeneities and screening strategy for metabolic dysfunction-associated fatty liver disease (MAFLD). Clin Chim Acta. 2023;538:203\u201310.","journal-title":"Clin Chim Acta"},{"key":"4842_CR20","doi-asserted-by":"publisher","unstructured":"Naja K, Anwardeen N, Elrayess MA. Metabolomic Signatures of MASLD Identified by the Fatty Liver Index Reveal Gamma-Glutamyl Cycle Disruption and Lipid Remodeling. Metabolites. 2025. https:\/\/doi.org\/10.3390\/metabo15110687.","DOI":"10.3390\/metabo15110687"},{"issue":"2","key":"4842_CR21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1053\/j.gastro.2018.06.031","volume":"155","author":"G Musso","year":"2018","unstructured":"Musso G, Cassader M, Paschetta E, Gambino R. Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis. Gastroenterology. 2018;155(2):282\u2013302. e288.","journal-title":"Gastroenterology"},{"issue":"4","key":"4842_CR22","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/hep.21763","volume":"46","author":"P Puri","year":"2007","unstructured":"Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, Contos MJ, Sanyal AJ. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007;46(4):1081\u201390.","journal-title":"Hepatology"},{"issue":"6","key":"4842_CR23","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1002\/hep.23229","volume":"50","author":"P Puri","year":"2009","unstructured":"Puri P, Wiest MM, Cheung O, Mirshahi F, Sargeant C, Min HK, et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology. 2009;50(6):1827\u201338.","journal-title":"Hepatology"},{"issue":"4","key":"4842_CR24","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41579-022-00805-x","volume":"21","author":"SL Collins","year":"2023","unstructured":"Collins SL, Stine JG, Bisanz JE, Okafor CD, Patterson AD. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nat Rev Microbiol. 2023;21(4):236\u201347.","journal-title":"Nat Rev Microbiol"},{"issue":"7","key":"4842_CR25","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nrgastro.2016.85","volume":"13","author":"C Leung","year":"2016","unstructured":"Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13(7):412\u201325.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"4842_CR26","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1111\/cas.15142","volume":"112","author":"N Ohtani","year":"2021","unstructured":"Ohtani N, Hara E. Gut-liver axis-mediated mechanism of liver cancer: a special focus on the role of gut microbiota. Cancer Sci. 2021;112(11):4433\u201343.","journal-title":"Cancer Sci"},{"issue":"9","key":"4842_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0304-5","volume":"51","author":"ZH Zhao","year":"2019","unstructured":"Zhao ZH, Xin FZ, Xue Y, Hu Z, Han Y, Ma F, et al. Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats. Exp Mol Med. 2019;51(9):1\u201314.","journal-title":"Exp Mol Med"},{"key":"4842_CR28","doi-asserted-by":"publisher","first-page":"964477","DOI":"10.3389\/fimmu.2022.964477","volume":"13","author":"D Zhou","year":"2022","unstructured":"Zhou D, Zhang J, Xiao C, Mo C, Ding BS. Trimethylamine-N-oxide (TMAO) mediates the crosstalk between the gut microbiota and hepatic vascular niche to alleviate liver fibrosis in nonalcoholic steatohepatitis. Front Immunol. 2022;13:964477.","journal-title":"Front Immunol"},{"issue":"1","key":"4842_CR29","doi-asserted-by":"publisher","first-page":"102522","DOI":"10.1016\/j.xcrm.2025.102522","volume":"7","author":"Y Huang","year":"2026","unstructured":"Huang Y, Li J, Song S, Du B, Cao Y, Wang Y, et al. Blood metabolic panels for identifying significant fibrosis and inflammation in patients with MASLD. Cell Rep Med. 2026;7(1):102522.","journal-title":"Cell Rep Med"},{"key":"4842_CR30","doi-asserted-by":"crossref","unstructured":"Grzych G, Vonghia L, Bout MA, Weyler J, Verrijken A, Dirinck E, Chevalier Curt MJ, Van Gaal L, Paumelle R, Francque S, et al. Plasma BCAA changes in patients with NAFLD are sex dependent. J Clin Endocrinol Metab. 2020;105(7):dgaa175.","DOI":"10.1210\/clinem\/dgaa175"},{"issue":"10","key":"4842_CR31","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","volume":"67","author":"N Jiao","year":"2018","unstructured":"Jiao N, Baker SS, Chapa-Rodriguez A, Liu W, Nugent CA, Tsompana M, et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut. 2018;67(10):1881\u201391.","journal-title":"Gut"},{"issue":"6","key":"4842_CR32","doi-asserted-by":"publisher","first-page":"100479","DOI":"10.1016\/j.jhepr.2022.100479","volume":"4","author":"B Paul","year":"2022","unstructured":"Paul B, Lewinska M, Andersen JB. Lipid alterations in chronic liver disease and liver cancer. JHEP Rep. 2022;4(6):100479.","journal-title":"JHEP Rep"},{"issue":"5","key":"4842_CR33","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3390\/arm92050037","volume":"92","author":"EHI Eliwa","year":"2024","unstructured":"Eliwa EHI, Mohamed El Koshiry A, Abd El-Hafeez T, Omar A. Secure and transparent lung and colon cancer classification using blockchain and Microsoft Azure. Adv Respir Med. 2024;92(5):395\u2013420.","journal-title":"Adv Respir Med"},{"issue":"1","key":"4842_CR34","doi-asserted-by":"publisher","first-page":"37170","DOI":"10.1038\/s41598-025-24850-7","volume":"15","author":"T Abd El-Hafeez","year":"2025","unstructured":"Abd El-Hafeez T, Tarek M, Sayed A. Optimizing YOLOv11 for automated classification of breast cancer in medical images. Sci Rep. 2025;15(1):37170.","journal-title":"Sci Rep"},{"key":"4842_CR35","first-page":"100787","volume":"32","author":"EHI Eliwa","year":"2025","unstructured":"Eliwa EHI, Abd El-Hafeez TJEIJ. A robust deep learning pipeline for multi-class cervical cancer cell identification. Egypt Inf J. 2025;32:100787.","journal-title":"Egypt Inf J"},{"key":"4842_CR36","doi-asserted-by":"publisher","first-page":"e3135","DOI":"10.7717\/peerj-cs.3135","volume":"11","author":"EHI Eliwa","year":"2025","unstructured":"Eliwa EHI, Abd El-Hafeez T. Particle swarm optimization framework for Parkinson\u2019s disease prediction. PeerJ Comput Sci. 2025;11:e3135.","journal-title":"PeerJ Comput Sci"},{"key":"4842_CR37","doi-asserted-by":"crossref","unstructured":"Omar A, Abd El-Hafeez TJNC, Applications. Optimizing epileptic seizure recognition performance with feature scaling and dropout layers. Neural Comput Appl. 2024;36(6):2835\u201352.","DOI":"10.1007\/s00521-023-09204-6"},{"issue":"1","key":"4842_CR38","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s40537-024-01011-7","volume":"11","author":"A Ameen","year":"2024","unstructured":"Ameen A, Fattoh IE, Abd El-Hafeez T, Ahmed K. Advances in ECG and PCG-based cardiovascular disease classification: a review of deep learning and machine learning methods. J Big Data. 2024;11(1):159.","journal-title":"J Big Data"},{"issue":"10","key":"4842_CR39","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/hep4.1417","volume":"3","author":"RD Khusial","year":"2019","unstructured":"Khusial RD, Cioffi CE, Caltharp SA, Krasinskas AM, Alazraki A, Knight-Scott J, et al. Development of a plasma screening panel for pediatric nonalcoholic fatty liver disease using metabolomics. Hepatol Commun. 2019;3(10):1311\u201321.","journal-title":"Hepatol Commun"},{"key":"4842_CR40","doi-asserted-by":"publisher","unstructured":"Moskaleva NE, Shestakova KM, Kukharenko AV, Markin PA, Kozhevnikova MV, Korobkova EO, et al. Target Metabolome Profiling-Based Machine Learning as a Diagnostic Approach for Cardiovascular Diseases in Adults. Metabolites. 2022. https:\/\/doi.org\/10.3390\/metabo12121185.","DOI":"10.3390\/metabo12121185"},{"key":"4842_CR41","doi-asserted-by":"publisher","unstructured":"Chae W, Lee KJ, Huh KY, Moon JS, Ko JS, Cho JY. Association of Metabolic Signatures with Nonalcoholic Fatty Liver Disease in Pediatric Population. Metabolites. 2022. https:\/\/doi.org\/10.3390\/metabo12090881.","DOI":"10.3390\/metabo12090881"},{"key":"4842_CR42","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.csbj.2024.01.007","volume":"23","author":"J Chen","year":"2024","unstructured":"Chen J, Lu RS, Diaz-Canestro C, Song E, Jia X, Liu Y, et al. Distinct changes in serum metabolites and lipid species in the onset and progression of NAFLD in obese Chinese. Comput Struct Biotechnol J. 2024;23:791\u2013800.","journal-title":"Comput Struct Biotechnol J"},{"key":"4842_CR43","doi-asserted-by":"publisher","unstructured":"Ji M, Jo Y, Choi SJ, Kim SM, Kim KK, Oh BC, et al. Plasma Metabolomics and Machine Learning-Driven Novel Diagnostic Signature for Non-Alcoholic Steatohepatitis. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10071669.","DOI":"10.3390\/biomedicines10071669"},{"key":"4842_CR44","doi-asserted-by":"publisher","first-page":"103661","DOI":"10.1016\/j.ebiom.2021.103661","volume":"73","author":"M Lewinska","year":"2021","unstructured":"Lewinska M, Santos-Laso A, Arretxe E, Alonso C, Zhuravleva E, Jimenez-Aguero R, et al. The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma. EBioMedicine. 2021;73:103661.","journal-title":"EBioMedicine"},{"issue":"1","key":"4842_CR45","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/HEP.0000000000000542","volume":"79","author":"M Noureddin","year":"2024","unstructured":"Noureddin M, Truong E, Mayo R, Mart\u00ednez-Arranz I, Minchol\u00e9 I, Banales JM, et al. Serum identification of at-risk MASH: the metabolomics-advanced steatohepatitis fibrosis score (MASEF). Hepatology. 2024;79(1):135\u201348.","journal-title":"Hepatology"},{"key":"4842_CR46","doi-asserted-by":"publisher","first-page":"154005","DOI":"10.1016\/j.metabol.2019.154005","volume":"101","author":"N Perakakis","year":"2019","unstructured":"Perakakis N, Polyzos SA, Yazdani A, Sala-Vila A, Kountouras J, Anastasilakis AD, et al. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: a proof of concept study. Metabolism. 2019;101:154005.","journal-title":"Metabolism"},{"issue":"7","key":"4842_CR47","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41592-021-01197-1","volume":"18","author":"S Alseekh","year":"2021","unstructured":"Alseekh S, Aharoni A, Brotman Y, Contrepois K, D\u2019Auria J, Ewald J, Fraser JCE, Giavalisco PD, Hall P. Mass spectrometry-based metabolomics: a guide for annotation, quantification and best reporting practices. Nat Methods. 2021;18(7):747\u201356.","journal-title":"Nat Methods"},{"issue":"10","key":"4842_CR48","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1136\/gutjnl-2018-317584","volume":"68","author":"C Caussy","year":"2019","unstructured":"Caussy C, Ajmera VH, Puri P, Hsu CL, Bassirian S, Mgdsyan M, et al. Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease. Gut. 2019;68(10):1884\u201392.","journal-title":"Gut"},{"issue":"5","key":"4842_CR49","doi-asserted-by":"publisher","first-page":"100477","DOI":"10.1016\/j.jhepr.2022.100477","volume":"4","author":"AJ McGlinchey","year":"2022","unstructured":"McGlinchey AJ, Govaere O, Geng D, Ratziu V, Allison M, Bousier J, et al. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. JHEP Rep. 2022;4(5):100477.","journal-title":"JHEP Rep"},{"issue":"8","key":"4842_CR50","doi-asserted-by":"publisher","first-page":"100845","DOI":"10.1016\/j.jlr.2025.100845","volume":"66","author":"RB Pebriana","year":"2025","unstructured":"Pebriana RB, Chen T, Derks RJE, Blomberg N, Grefhorst A, Mohammed Y, et al. Non-invasive identification of steatohepatitis in patients with MASLD using a sterol and lipidomic signature. J Lipid Res. 2025;66(8):100845.","journal-title":"J Lipid Res"},{"key":"4842_CR51","doi-asserted-by":"publisher","unstructured":"Sun C, Guo Y, Cong P, Tian Y, Gao X. Liver lipidomics analysis revealed the novel ameliorative mechanisms of L-carnitine on high-fat diet-induced NAFLD mice. Nutrients. 2023. https:\/\/doi.org\/10.3390\/nu15061359.","DOI":"10.3390\/nu15061359"},{"key":"4842_CR52","doi-asserted-by":"publisher","first-page":"1673002","DOI":"10.3389\/fnut.2025.1673002","volume":"12","author":"RMG Gowda","year":"2025","unstructured":"Gowda RMG, Sg D, Upadhyay BG, Chainani G, Kain N. Effect of exercise on multi-compartment lipid metabolism in murine models fed an obesogenic diet using non-targeted LC\/MS. Front Nutr. 2025;12:1673002.","journal-title":"Front Nutr"},{"key":"4842_CR53","doi-asserted-by":"publisher","first-page":"1665421","DOI":"10.3389\/fphar.2025.1665421","volume":"16","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Xu X, Fan X, Wu Y, Zhang X, Wu Y, et al. Unraveling p-Cresol: from biosynthesis to biological and biochemical activities. Front Pharmacol. 2025;16:1665421.","journal-title":"Front Pharmacol"},{"issue":"32","key":"4842_CR54","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1093\/eurheartj\/ehad333","volume":"44","author":"I Nemet","year":"2023","unstructured":"Nemet I, Li XS, Haghikia A, Li L, Wilcox J, Romano KA, et al. Atlas of gut microbe-derived products from aromatic amino acids and risk of cardiovascular morbidity and mortality. Eur Heart J. 2023;44(32):3085\u201396.","journal-title":"Eur Heart J"},{"issue":"1","key":"4842_CR55","doi-asserted-by":"publisher","first-page":"10663","DOI":"10.1038\/s41598-019-47216-2","volume":"9","author":"K Enooku","year":"2019","unstructured":"Enooku K, Nakagawa H, Fujiwara N, Kondo M, Minami T, Hoshida Y, et al. Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma. Sci Rep. 2019;9(1):10663.","journal-title":"Sci Rep"},{"key":"4842_CR56","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.nutres.2025.12.010","volume":"146","author":"H Li","year":"2025","unstructured":"Li H, Li M, Fei S, Xie T, Guo L, Pan Q. Elevated C18:1-acylcarnitine is associated with a higher fibrosis-4 index through inflammation mediation: a cross-sectional study. Nutr Res. 2025;146:97\u2013110.","journal-title":"Nutr Res"},{"issue":"10","key":"4842_CR57","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1038\/nutd.2013.33","volume":"3","author":"G la Marca","year":"2013","unstructured":"la Marca G, Malvagia S, Toni S, Piccini B, Di Ciommo V, Bottazzo GF. Children who develop type 1 diabetes early in life show low levels of carnitine and amino acids at birth: does this finding shed light on the etiopathogenesis of the disease? Nutr Diabetes. 2013;3(10):e94.","journal-title":"Nutr Diabetes"},{"key":"4842_CR58","doi-asserted-by":"publisher","first-page":"156063","DOI":"10.1016\/j.metabol.2024.156063","volume":"162","author":"S Muralidharan","year":"2025","unstructured":"Muralidharan S, Lee JWJ, Lim YS, Muthiah M, Tan E, Demicioglu D, et al. Serum lipidomic signatures in patients with varying histological severity of metabolic-dysfunction associated steatotic liver disease. Metabolism. 2025;162:156063.","journal-title":"Metabolism"},{"key":"4842_CR59","doi-asserted-by":"publisher","unstructured":"Lim AS, Cruz SN, Uddin AA, Malysheva O, Caudill MA, Alonso C, Montilla A, Karsdal MA, Leeming DJ, Mayorca-Guiliani AE, et al. Pilot trials of oral betaine in participants with metabolic dysfunction-associated steatotic liver disease and elevated alanine aminotransferase. Hepatology 2025. https:\/\/doi.org\/10.1097\/HEP.0000000000001477.","DOI":"10.1097\/HEP.0000000000001477"},{"issue":"1","key":"4842_CR60","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1017\/S0954422421000056","volume":"35","author":"W Chen","year":"2022","unstructured":"Chen W, Xu M, Xu M, Wang Y, Zou Q, Xie S, Wang L. Effects of betaine on non-alcoholic liver disease. Nutr Res Rev. 2022;35(1):28\u201338.","journal-title":"Nutr Res Rev"},{"key":"4842_CR61","doi-asserted-by":"publisher","unstructured":"Banerjee R, Wehrle CJ, Wang Z, Wilcox JD, Uppin V, Varadharajan V, et al. Circulating gut microbe-derived metabolites are associated with hepatocellular carcinoma. Biomedicines. 2024. https:\/\/doi.org\/10.3390\/biomedicines12091946.","DOI":"10.3390\/biomedicines12091946"},{"issue":"11","key":"4842_CR62","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1073\/pnas.1316569111","volume":"111","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, Jameson E, Crosatti M, Schafer H, Rajakumar K, Bugg TD, Chen Y. Carnitine metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota. Proc Natl Acad Sci U S A. 2014;111(11):4268\u201373.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"27","key":"4842_CR63","doi-asserted-by":"publisher","first-page":"11138","DOI":"10.1074\/jbc.R117.779678","volume":"292","author":"R Rossner","year":"2017","unstructured":"Rossner R, Kaeberlein M, Leiser SF. Flavin-containing monooxygenases in aging and disease: emerging roles for ancient enzymes. J Biol Chem. 2017;292(27):11138\u201346.","journal-title":"J Biol Chem"},{"issue":"3","key":"4842_CR64","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.celrep.2014.12.036","volume":"10","author":"M Warrier","year":"2015","unstructured":"Warrier M, Shih DM, Burrows AC, Ferguson D, Gromovsky AD, Brown AL, et al. The TMAO-generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance. Cell Rep. 2015;10(3):326\u201338.","journal-title":"Cell Rep"},{"issue":"3","key":"4842_CR65","doi-asserted-by":"publisher","first-page":"e70092","DOI":"10.1002\/fsn3.70092","volume":"13","author":"D Hashemi","year":"2025","unstructured":"Hashemi D, Fard MV, Mohammadhasani K, Barati M, Nattagh-Eshtivani E. Carotenoids improve obesity and fatty liver disease via gut microbiota: a narrative review. Food Sci Nutr. 2025;13(3):e70092.","journal-title":"Food Sci Nutr"},{"issue":"26","key":"4842_CR66","doi-asserted-by":"publisher","first-page":"8061","DOI":"10.3748\/wjg.v21.i26.8061","volume":"21","author":"X Qiu","year":"2015","unstructured":"Qiu X, Gao DH, Xiang X, Xiong YF, Zhu TS, Liu LG, Sun XF, Hao LP. Ameliorative effects of lutein on non-alcoholic fatty liver disease in rats. World J Gastroenterol. 2015;21(26):8061\u201372.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"4842_CR67","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4162\/nrp.2012.6.2.113","volume":"6","author":"JE Kim","year":"2012","unstructured":"Kim JE, Clark RM, Park Y, Lee J, Fernandez ML. Lutein decreases oxidative stress and inflammation in liver and eyes of guinea pigs fed a hypercholesterolemic diet. Nutr Res Pract. 2012;6(2):113\u20139.","journal-title":"Nutr Res Pract"},{"key":"4842_CR68","doi-asserted-by":"publisher","unstructured":"Chai W, Tao MH. Overall and sex-specific associations of serum lipid-soluble micronutrients with metabolic dysfunction-associated steatotic liver disease among adults in the United States. Nutrients. 2024. https:\/\/doi.org\/10.3390\/nu16081242.","DOI":"10.3390\/nu16081242"},{"key":"4842_CR69","doi-asserted-by":"publisher","first-page":"908011","DOI":"10.3389\/fmicb.2022.908011","volume":"13","author":"Y Ni","year":"2022","unstructured":"Ni Y, Lu M, Xu Y, Wang Q, Gu X, Li Y, et al. The role of gut microbiota-bile acids axis in the progression of non-alcoholic fatty liver disease. Front Microbiol. 2022;13:908011.","journal-title":"Front Microbiol"},{"key":"4842_CR70","doi-asserted-by":"publisher","first-page":"1288856","DOI":"10.3389\/fmicb.2024.1288856","volume":"15","author":"J Zhang","year":"2024","unstructured":"Zhang J, Zhou J, He Z, Li H. Bacteroides and NAFLD: pathophysiology and therapy. Front Microbiol. 2024;15:1288856.","journal-title":"Front Microbiol"},{"issue":"1","key":"4842_CR71","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12866-024-03328-y","volume":"24","author":"J Li","year":"2024","unstructured":"Li J, Ye S, Huang X, Yang G, Wang Y, Zeng J, et al. Analysis of the intestinal microbiota and profiles of blood amino acids and acylcarnitines in neonates with hyperbilirubinemia. BMC Microbiol. 2024;24(1):171.","journal-title":"BMC Microbiol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04842-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04842-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04842-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T01:03:57Z","timestamp":1781571837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04842-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4842"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04842-1","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods adhered to relevant guidelines and regulations and were approved by the ethics committee of the Second Xiangya Hospital of Central South University (number 2023-Z0168). The requirement for written informed consent was waived due to the retrospective design, in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"361"}}